Irving G. Joshua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irving G. Joshua has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Adrienne P. Bratcher
Department of Physiology and Biophysics, School of Medicine, University of Louisville, Louisville, Kentucky 40292
1 shared publicationJeff C. Falcone
Department of Physiology and Biophysics, School of Medicine, University of Louisville, Louisville, Kentucky 40292
1 shared publicationQin Zhang
Department of Physiology and Biophysics, School of Medicine, University of Louisville, Louisville, Kentucky 40292
1 shared publicationSuresh C. Tyagi
Department of Physiology and Biophysics, School of Medicine, University of Louisville, Louisville, Kentucky 40292
1 shared publicationWalter E. Rodriguez
Department of Physiology and Biophysics, School of Medicine, University of Louisville, Louisville, Kentucky 40292
1 shared publication
Latest Publications
- 26 September 2005
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 96 (6) , 1149-1156
Mechanisms of endothelial dysfunction with development of type 1 diabetes mellitus: Role of insulin and C‐peptide
Complications associated with insulin‐dependent diabetes mellitus (type‐1diabetes) primarily represent vascular dysfunction that has its origin in the endothelium. While many of the vascular changes are more accountable in the late stages of type‐1diabetes, changes that occur in the early or initial functional stages of this disease may precipitate these later complications. The early stages of type‐1diabetes are characterized by a diminished production of both insulin and C‐peptide with a significant hyperglycemia. During the last decade numerous speculations and theories have been developed to try to explain the mechanisms responsible for the selective changes in vascular reactivity and/or tone and the vascular permeability changes that characterize the development of type‐1diabetes. Much of this research has suggested that hyperglycemia and/or the lack of insulin may mediate the observed functional changes in both endothelial cells and vascular smooth muscle. Recent studies suggest several possible mechanisms that might be involved in the observed decreases in vascular nitric oxide (NO) availability with the development of type‐1 diabetes. In addition more recent studies have indicated a direct role for both endogenous insulin and C‐peptide in the amelioration of the observed endothelial dysfunction. These results suggest a synergistic action between insulin and C‐peptide that facilitates increase NO availability and may suggest new clinical treatment modalities for type‐1 diabetes mellitus.
- 26 September 2005
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 96 (6) , 1149-1156
Mechanisms of endothelial dysfunction with development of type 1 diabetes mellitus: Role of insulin and C‐peptide
Complications associated with insulin‐dependent diabetes mellitus (type‐1diabetes) primarily represent vascular dysfunction that has its origin in the endothelium. While many of the vascular changes are more accountable in the late stages of type‐1diabetes, changes that occur in the early or initial functional stages of this disease may precipitate these later complications. The early stages of type‐1diabetes are characterized by a diminished production of both insulin and C‐peptide with a significant hyperglycemia. During the last decade numerous speculations and theories have been developed to try to explain the mechanisms responsible for the selective changes in vascular reactivity and/or tone and the vascular permeability changes that characterize the development of type‐1diabetes. Much of this research has suggested that hyperglycemia and/or the lack of insulin may mediate the observed functional changes in both endothelial cells and vascular smooth muscle. Recent studies suggest several possible mechanisms that might be involved in the observed decreases in vascular nitric oxide (NO) availability with the development of type‐1 diabetes. In addition more recent studies have indicated a direct role for both endogenous insulin and C‐peptide in the amelioration of the observed endothelial dysfunction. These results suggest a synergistic action between insulin and C‐peptide that facilitates increase NO availability and may suggest new clinical treatment modalities for type‐1 diabetes mellitus.